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Abstract: Chemotherapy-induced alopecia (CIA) is a common side effect of conventional
chemotherapy and represents a major problem in clinical oncology. Even months after the end
of chemotherapy, many cancer patients complain of hair loss, a condition that is psychologically
difficult to manage. CIA disturbs social and sexual interactions and causes anxiety and depression.
Synthetic drugs protecting from CIA and endowed with hair growth stimulatory properties are
prescribed with caution by oncologists. Hormones, growth factors, morphogens could unwontedly
protect tumour cells or induce cancer cell proliferation and are thus considered incompatible with
many chemotherapy regimens. Nutraceuticals, on the contrary, have been shown to be safe and
effective treatment options for hair loss. We here show that polyphenols from Malus Pumila Miller cv
Annurca are endowed with hair growth promoting activity and can be considered a safe alternative
to avoid CIA. In vitro, Annurca Apple Polyphenolic Extract (AAE) protects murine Hair Follicles
(HF) from taxanes induced dystrophy. Moreover, in virtue of its mechanism of action, AAE is
herein proven to be compatible with chemotherapy regimens. AAE forces HFs to produce ATP
using mitochondrial β-oxidation, reducing Pentose Phosphate Pathway (PPP) rate and nucleotides
production. As consequence, DNA replication and mitosis are not stimulated, while a pool
of free amino acids usually involved in catabolic reactions are spared for keratin production.
Moreover, measuring the effect exerted on Poly Unsaturated Fatty Acid (PUFA) metabolism, we prove
that AAE promotes hair-growth by increasing the intracellular levels of Prostaglandins F2α (PGF2α)
and by hijacking PUFA catabolites toward β-oxidation.
Keywords: nutraceuticals; apple polyphenols; PUFA; Prostaglandins F2; taxanes; chemotherapy
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1. Introduction
The process of extension of hair shaft in humans occurs in a specific phase of the hair follicle
(HF) cycle, the anagen. Each anagen phase can last years and is interspersed with short lasting
phases of degeneration (catagen) and resting, (telogen) [1]. Hair shaft extension is sustained by highly
proliferating cells of the hair matrix (HMs). These differentiate into several cell lineages, (among these
cells of the outer (ORS) and inner (IRS) root sheaths) all differently specialized in the production and
modification of hair keratins [1–4].
In virtue of their high rate of proliferation, healthy HFs cells are easy victims of chemotherapy
agents [5–9]. Anticancer drugs impair mitosis and induce premature apoptosis, HF miniaturization
and hair bulb dystrophy [10,11]. The resulting chemotherapy-induced alopecia (CIA) is one of the
most common side events caused by conventional cytotoxic chemotherapy and represents a major
problem in clinical oncology [12]. Chemotherapy regimens based on doxorubicin, anthracycline,
cyclophosphamide and taxanes lead to massive apoptosis in HM keratinocytes followed by a transitory
or even irreversible hair loss. In particular, patients in taxane regimen undergo irreversible alopecia
more than those treated with other classes of chemotherapy agents [13].
CIA is not life-threatening, however it represents a psychologically difficult event to manage,
especially for women. The stigma of CIA are distressing, disturb social interactions, cause loss in
self-confidence and self-esteem, alteration in sexuality and induce anxiety and depression [14].
Up to today, no treatment is currently available to prevent or retard CIA. This gap is also due
to an understandable reluctance of oncologists. Priority for the physicians is and must remain the
eradication of cancer cells and the avoidance of tumour relapses. The usage of agents protecting HFs
from CIA could unwontedly stimulate cancer cell proliferation, an event definitely more dangerous
than hair loss. In virtue of their ability to induce proliferation in virtually any healthy and cancer
cell, hormones endowed with hair stimulating activity, hair growth factors, HF morphogens (like the
Wnt/β-catenin pathway agonists Valproic acid, Lithium Chloride and Wnt7a) [15–17] are all considered
incompatible with chemotherapy regimens.
Recently, nutritional and antioxidant therapies have been shown to be effective options for hair
loss and, in virtue of their safety, are becoming popular over-the-counter products. We have shown
that nutraceuticals obtained from Malus Pumila Miller cv Annurca, an apple native to Southern Italy
and highly enriched in Procyanidin B2, are able to promote hair growth and keratin expression
in humans [18,19]. In a clinical trial describing the effect of Annurca Apple polyphenolic extract
(AAE) on hair growth in healthy subjects, the consumption of AAE exerted significant results in
terms of hair number, hair weight and keratin content [20]. Recently, we have started elucidating
the molecular details behind the hair growth promoting effect of AAE and have shown that this
does not result from stimulation of HF cell proliferation [21]. Topical treatment with a cosmetic
foam containing AAE strongly affects, in vivo, the overall red-ox environment of healthy HF cells
forcing them through a drastic metabolic switch. While HFs normally produce ATP via aerobic
glycolysis, glutaminolysis and Pentose Phosphate Pathway (PPP) [22], AAE forces HFs to produce
ATP using mitochondrial β-oxidation. In the presence of active mitochondria, HFs thus spare amino
acids (mainly Glutamine, Glycine, Arginine and Cysteine) from oxidation and use them for keratin
production. Moreover, as consequence of the metabolic switch, the syntheses of nitrogen containing
bases and of deoxy-nucleotides in HFs are inhibited by AAE. The absence of metabolites necessary for
DNA replication, RNA production and mitosis confirms that AAE hair growth stimulation does not
rely on induction of cell proliferation.
Herein, we analyse new aspects of the molecular mechanism behind AAE activity by analysing
how the apple extract affects the metabolism of PUFA, a class of lipids and signalling molecules
involved in HFs homeostasis [23–26]. PUFA signalling influences as well response to chemotherapy
and is extremely important in terms of immunosuppression, tumour growth and tumour relapse [27,28].
Arachidonic Acid (ARA), aω-6 PUFA, significantly promotes hair shaft elongation and proliferation
of HM keratinocytes in ex-vivo HF cultures [29,30]. Nowadays, clinical trials are running to test the
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hair growth promotion induced by latanoprost [31] and isopropyl unoprostone [32], both analogues of
Prostaglandin F2α, one of the major metabolite of ARA.
We treated C57BL/6 mice with a cosmetic foam containing AAE (topically and for 4 weeks) to then
extract their HFs and analyse their metabolome by Direct Infusion Fourier Transform-ion cyclotron
resonance mass spectrometry (FT-ICR-MS), a technique endowed with ultra-high mass accuracy
and resolution [33]. We prove that AAE increases the intracellular levels of the growth promoting
prostanoid Prostaglandins F2α (PGF2α). On the contrary, AAE reduces the intracellular levels of PUFA
epoxides stimulating their conversion into the corresponding inactive diols and promoting their usage
as β-oxidation substrates.
We finally use an in vitro assay and prove for the first time that AAE can inhibit taxane induced
dystrophy in ex-vivo murine HFs. The increase in keratin production, the lack of stimulation of cell
proliferation and mitosis, the modulation of lipid molecules all suggest that AAE could represent
a safe nutraceutical for hair growth and an interesting alternative to synthetic drugs for treating CIA.
In taxane-containing chemotherapy regimen, AAE could be even more indicated, considering the
selectivity of this chemotherapy agent for mitotic cells.
2. Materials and Methods
2.1. Reagents and Nutraceuticals
AAE Annurca Apple Extract AnnurtriComplex (industrial procyanidinic extract of Annurca
apple PGI (Protected Geographical Indication) (Malus Pumila Miller cv Annurca)) was produced by
MB-Med (Turin, Italy) as already described [34]. For in vitro experiments it was dissolved in DMSO to
achieve a stock concentration of 30 mg/mL and stored at −20 ◦C in the dark. Composition of AAE
cosmetic foam: AnnurtriComplex 6% (w/v), water, glycerin, decylglucoside, polysorbate, maltodextrin,
potassium sorbate, sodium benzoate, silica. The Placebo foam was formulated identically but did not
contain AnnurtriComplex. DAPI was from Sigma Chemical Co. (St. Louis, MO, USA) was used as
already described [35]. Paclitaxel and Docetaxel were kindly provided by the Hospital Pharmacy of
Istituto Nazionale Tumori-IRCCS-FondazioneG. Pascale.
2.2. Animals
2.2.1. Animals for Ex-Vivo Culturing of Murine HFs
Wild-type C57BL/6 mice were used for the ex vivo experiments. Only male animals were used
in this study. All animal experiments were performed in compliance with ethical guidelines and
approved by the University of Naples Federico II. 12 weeks old mice (postnatal day 84) were sacrificed
and their dorsal skin were immediately excised and immersed in Phosphate Buffer Saline (PBS). 1 cm2
of skin biopsies, were rinsed in PBS and located in 6 multiwell plates. Biopsies were cultivated in 1 mL
of Dulbecco Modified Eagle Medium (41965-039, GIBCO, Thermo Fisher Scientific, Waltham, MA,
USA) supplemented with 10% FBS (10270, GIBCO), Glutamine (35050-061, GIBCO), Penicillin and
Streptomycin (15070-063, GIBCO). Tissues were incubated for 8 days in a Cell Culture incubator at
37 ◦C, supplemented with 5% CO2. When indicated, Paclitaxel (700 nM), Docetaxel (700 nM) and/or
AAE (400 mg/L) were added to the culture medium. The medium was replenished every 3 days.
At the end of the incubation, tissues were rinsed three times in DMEM and fixed in 4% formaldehyde
diluted in PBS (pH 7.4). Nuclei were stained with DAPI and visualized under a fluorescent microscope
as already described [35]. Scanning Electron Microscopy (SEM) and Energy Dispersive X-Ray (EDX)
analysis of hair shafts were performed with a bench top Phenom XL (Alfatest, Milan, Italy) following
manufacturer instructions and as already described [36].
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2.2.2. Animals for In-Vivo Experiments
Wild-type C57BL/6 mice (7 weeks old, postnatal day 49) were used in all experiments to test the
effect of cosmetic foam containing AAE. All animals received human care and were maintained in
separate cages at 22 ◦C–24 ◦C and fed a general rodent diet. Differently from other published protocols,
here animals were left unshaved and received a topical treatment with 2 cm3 of the indicated cosmetic
foam for 4 weeks. Only male animals were used in this study. All animal experiments were performed
in compliance with ethical guidelines and approved by the University of Naples Federico II.
2.3. Metabolite Extraction from Murine Tissues
Immediately after excision, tissues were rinsed and kept in PBS. Hair shafts were plucked out with
a sterile tweezers and immediately covered with a solution of PBS at R.T. To allow detachment of HF cells,
plucked HFs were incubated for 15 min in PBS supplemented with 5 mM EDTA. Hair shafts were removed
with a cell strainer and HF cells were centrifuged for 5 min at 500 rpm. The cell pellets were washed twice
in PBS to be then homogenized in 1 mL of pre-chilled methanol/water 1:1 solution containing 10 nmol of
internal standard and finally centrifuged at 10,000× g for 10 min at 4 ◦C [37]. The resulting supernatants
were collected and transferred into new Eppendorf tubes and stored at−80 ◦C.
2.4. Mass Spectrometry-Based Metabolomic, Statistics and Analysis
Analyses were performed in direct infusion following a previous protocol [33,38] employing
a Hamilton syringe (250 µL) at a flow rate of 2 µL/min. Data were acquired on a SolariX XR
7T (Bruker Daltonics, Bremen, Germany). The instrument was tuned with a standard solution of
sodium trifluoroacetate. Mass Spectra were recorded in broadband mode in the range 100–1500 m/z,
with an ion accumulation of 20 ms, with 32 scans using 2 million data points (2M). Nebulizing (N2)
and drying gases (air) were set at 1 and 4 mL/min, respectively, with a drying temperature of 200 ◦C.
Both positive and negative ESI ionization were employed. Five replicates of each injection were
carried out. The instrument was controlled by Bruker FTMS Control, MS spectra were elaborated with
Compass Data Analysis version 4.2 (Bruker, New York, NY, USA), identification of compounds based
on accurate MS measurements was performed by Compound Crawler ver. 3.0 and Metaboscape 3.0
(Bruker). Metabolites signals were normalized using internal standards. Comparisons and differences
were analysed for statistical significance by two-way Anova test and Bonferroni post-tests analysis.
All graphs, bars or lines indicate mean and error bars indicate standard error of the mean (s.e.m.).
Furthermore, Partial Least Square Discriminant Analysis (PLS-DA) was used as classification model.
All graphs, bars or lines indicate mean and error bars indicate standard error of the mean (s.e.m.).
Statistical analysis was performed using Statistica software (StatSoft, Tulsa, OK, USA) and Minitab
(Minitab Inc., State College, PA, USA).
3. Results
3.1. Topical Treatment with AAE Alters PUFAs Metabolism in Murine HFs
We started implementing our recently published metabolomic analysis [21] by investigating the
effect exerted by AAE on the metabolism of PUFAs. These lipids are present in an esterified form in all
mammalian cell membranes and are released for signalling purposes by the action of Phospholipase
A2. Free PUFA are made available as a substrate for the intercellular biosynthesis of various
metabolites through the action of cyclooxygenases (COX1, COX2), lipoxygenases (LOX5, LOX12/15)
and cytochrome P-450 (CYP). An increase in PUFAs after AAE treatment could have been indeed
represented a likely explanation for the hair growth promotion effect exerted by AAE. PUFA has been
reported to reduce UV-induced epidermal thickening [39] and effectively stimulates the duplication of
Dermal Papilla cells [29].
C57BL/6 mice were treated topically with a cosmetic foam supplemented either with AAE or
with a placebo. Foams were applied on the dorsal skin of 7 weeks old mice (HFs in telogen [40]).
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We have already shown that the cosmetic foam is able to accelerate telogen to anagen transition in
murine HFs and to alter the metabolism of HFs [21]. After 4 weeks of treatment, mice (11 week old)
were sacrificed and their dorsal skin excised. HFs were plucked out and their intracellular metabolites
extracted. Metabolites of HF cells were identified and measured by DI-FT-ICR mass spectrometry
and the levels of each metabolite in AAE and placebo treated HFs were compared. The high mass
accuracy (average: 0.087 ppm, Figure 1, Table 1 and Table S1), isotopic distribution and comparison
with available standards, ensured confident identification of the discussed metabolites.
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Figure 1. Topical treatm nt wi h AAE alters PUFAs tabolome in murine HFs. Schematic cartoon
depicting some of the metabolic reactions positively affected by AAE in murine HFs. Green arrowheads
indicate reactions stimulated by AAE. Green dots indicate metabolites, whose intracellular
concentration resulted increased by AAE. (COX cyclooxygenase; LOX, lipoxygenase; CYP, cytochrome
P450; sEH, soluble epoxide hydroxylase; n.e. non enzymatic. The abbreviations of PUFA metabolites as
well as their full IUPAC name are shown in Table S1).
Table 1. Fold induction for the indicated metabolites measured upon in vivo treatment with AAE.
PUFA Metabolite Fold Change 1 PUFA Metabolite Fold Ch ng 1
ARA DHA
ARA 20:4ω-6 * 1.0 ± 0.1 DHA 22:6ω-3 * 0.9 ± 0.2
Tetranor 12-H TE 3.4 ± 0.2 17-HDoHE 1.0 ± 0.1
14,15-DiHETrE 3.5 ± 0.1 13-HDoHE 1.1 ± 0.1
2,3-Dinor-6-keto-PGF1α 1.6 ± 0.2 19,20-DiHDPA 1.3 ± 0.1
15-Keto-13,14-dihydroPGA2 1.0 ± 0.1
PGF2α 1.6 ± 0.1 α-LA
13,14-dihydro-PGF2α 2.3 ± 0.2 α-LA 18:3ω-3 * 1.1 ± 0.1
15-deoxy-∆12,14-PGJ2 1.1 ± 0.1 LA
LA 18:2ω-6 * 0.9 ± 0.1
EPA 9,10-DHOME specific for AAE
EPA 20:5ω-3 * 0.9 ± 0.1 13-HpODE 2.3 ± 0.1
5-HEPE 1.0 ± 0.1 9,12,13-TriHOME 1.3 ± 0.1
1 (n = 15. Shown is mean ± s.e.m.); * indicates unprocessed PUFA. The abbreviations of PUFA metabolites as well
as their full IUPAC names are shown in Table S1.
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3.1.1. DHA, EPA, LA and α-LA Metabolites
We started looking at metabolites of Docosahexaenoic acid (DHA 22:6ω-3), an essential and very
abundant omega-3 fatty acid (Figure 1, Table 1 and Table S1). DHA intracellular levels were not
statistically altered by AAE (0.9 ± 0.2 fold, mean ± s.e.m., p value > 0.05).
The same was measured for 17-HDoHE (0.95 ± 0.1 fold, p value > 0.05) and 13-HDoHE
(1.1 ± 0.1 fold, p value > 0.05) two products of DHA non-enzymatic oxidation. On the contrary,
we measured a statistically significant elevation in 19,20-DiHDPA (1.3 ± 0.1 fold, p value < 0.01),
a DHA catabolite produced via: (i) CYP-catalysed epoxidation at the DHA omega-3 double bond,
followed by (ii) conversion to the vicinal diol by Epoxide Hydrolases (sEH).
We could as well identify in our metabolic analysis Eicosopentaneoic Acid (EPA 20:5ω-3) and
the product of its non-enzymatic oxidation, 5-HEPE (Figure 1, Table 1 and Table S1). However,
their intracellular levels (0.9 ± 0.1 fold, p value > 0.05 and 1.0 ± 0.1 fold, p value > 0.05) were unaltered
by the treatment with AAE. Similarly, the intracellular level of the PUFAs Linoleic acid (LA 18:2ω-6)
and α Linoleic acid (α LA 18:3ω-3) did not show to be altered by AAE (0.9 ± 0.1 fold, p value > 0.05;
1.1 ± 0.1 fold, p value > 0.05).
On the contrary, treatment with AAE increased in vivo the LA catabolites 9,10-DHOME
(specific for AAE and absent in HFs treated with placebo) and 9,12,13 TriHOME (1.3 ± 0.1 fold,
p value < 0.05). 9,10-DHOME originates from 9,10-EpOME, a leukotoxin obtained from LA by the
sequential reaction of CYP and sEH. 13-HpODE, another catabolite of LA produced by LOX12/15.,
resulted increased by AAE treatment (2.3 ± 0.1 fold, p value < 0.001)
3.1.2. ARA Catabolites (CYP and LOX Metabolites)
We then moved to analyse ARA 20:4ω-6 metabolism. Our metabolic analysis could identify
ARA (1.0 ± 0.1 fold, p value > 0.05) as well as its catabolites Tetranor (12-HETE) (3.4 ± 0.2 fold,
p value < 0.001) and 14,15 DiHeTre (3.5 ± 0.1 fold, p value < 0.001). Only the intracellular levels of
the ARA catabolites were increased upon treatment with AAE. In details, Tetranor (12-HETE) is the
product of β-oxidation of 12-HETE (the result of ARA oxidation by 12/15-LOX), while 14,15-DiHeTre
is the product of the hydrolysis catalysed by sEH of 14,15-HETE an epoxy-eicosatrienoic acid produced
by CYP from ARA.
3.1.3. AAE Accelerates Epoxides Conversion into Inactive Diols and β-Oxidation of PUFA Metabolites
The intracellular levels of the most abundant unprocessed PUFAs, ARA, EPA, LA, αLA and DHA
were thus not altered by AAE. Since PUFA release from membrane lipids is initiated when a specific
stimuli activate Phospholipase A2, our results point toward AAE not affecting Phospholipase A2
activity at least in murine HFs.
On the contrary AAE increased in vivo the intracellular levels of 19,20-DiHDPA, 9,10-DHOME,
14,15-DiHETrE. These PUFA catabolites all share a related origin. They are all diols deriving from
the corresponding PUFA epoxides, 19,20-HDPA (Epoxide of DPA), 9,10-epHOME (Epoxide of LA),
14,15-HETE (Epoxide of LA), respectively. In vivo, these epoxides are all generated by CYP epoxidase
and are endowed with anti-inflammatory properties [41]. PUFA epoxides are short living and are
converted into their inactive diols (among which 19,20-DiHDPA, 9,10-DHOME, 14,15-DiHETrE) by
the family of enzyme of soluble epoxidase hydrolases (sEH) [42]. sEH blocks the anti-inflammatory
activities of PUFA epoxides promoting their degradation via mitochondrial or peroxisomal β-oxidation.
β-oxidation of PUFA derived metabolites could also be the meaning behind the increase of
Tetranor 12-HETE. This metabolite is the major β-oxidation product of 12(S)-HETE a product of ARA
metabolism. All together our results seem to depict a scenario where ignition of mitochondrial activity
induced by AAE in HFs [21] hijacks many PUFA metabolites toward β-oxidation. PUFA epoxides are
thus converted into inactive diols, ultimately altering the overall balance of biologically active lipids
and signalling molecules in HFs.
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3.1.4. Prostaglandins
Finally we measure the intracellular levels of prostaglandins. PGD2 and PGE2 have been shown
to inhibit and stimulate hair growth, respectively [25,43–45] and PGF2 α has recently attracted the
interest of dermatologists in virtue of its stimulatory effect on hair growth. Patients affected by
glaucoma and receiving PGF2α analogues, claimed side effects such as cutaneous hypertrichosis
and hyperpigmentation of eyelashes [32]. PGF2α analogues latanoprost and bimatoprost are being
tested in clinical trials for Patterned Hair Loss and Androgenic Alopecia and are showing promising
results [4,31].
Analysis of prostaglandins was complicated by their isobaric molecular weights. Notwithstanding,
we could measure an increase of the intracellular levels of 2,3-Dinor-6-keto-PGF1α (1.6 ± 0.2 fold,
p value < 0.05), a major β-oxidation product of the prostacyclin PGI2. On the contrary AAE did not
increase the intracellular levels of 15-deoxy-∆12,14-prostaglandin J2 (1.1 ± 0.1 fold, p value > 0.05),
nor those of 13,14-dihydro-15-keto PGA2 (1.0 ± 0.1 fold, p value > 0.05), both non-enzymatic oxidation
products of PGD2 and PGE2, respectively, excluding their involvement in AAE mechanism.
Differently, AAE increased the intracellular level of PGF2alpha (1.6 ± 0.1 fold, p value < 0.05) and
13,14-dihydro PGF2α (2.3 ± 0.2 fold, p value < 0.001) a metabolite resulting from 13,14-dihydro-15
keto PGF2α.
3.1.5. AAE Selectively Activates Prostanoid Metabolism in HF Cells
The increase in PGF2α could be explained with a stimulatory activity exerted by AAE on COXs.
However, in our opinion this seems not be the case considering that PGD2, PGE2, PGI2 and PGF2α
are all produced starting from Prostaglandin H2 (PGH2), the main product of COXs activity on
ARA. In virtue of this, AAE should have up-regulated all the prostaglandins. We believe that the
selective increase in PGF2α production might reflect the selectivity of AAE for hair bulge cells of
the HFs, we already documented [21]. Enzymes producing PGF2α or converting PGE2 into PGF2α
are preferentially expressed in bulge cells and in ORS originating from them and only weakly in
HM and dermal papilla [23]. We have already shown that AAE seems to activate mitochondrial
activity specifically in hair bulge and ORS keratinocytes [21] sparing HM cells of the dermal papilla.
It is probably this selectivity of AAE toward specific HFs cells, to allow the increase of PGF2α
intracellular levels, leaving unaltered those of the other prostanoids. Despite this is a likely hypothesis,
further experiments will be necessary to confirm it.
3.2. AAE Protects Murine HFs from Taxane Induced Follicular Dystrophy
When cultivated in appropriate growth conditions, excised HFs may sustain in vitro hair shaft
extension. The resulting ex vivo culture preserves several biological properties of the HFs and respond
to chemotherapy agents showing some of the key features of CIA. Here we used skin biopsies of
12 week old C57BL/6 mice (anagen phase, [40]) to perform an ex-vivo incubation of HFs in the
presence of paclitaxel (700 nM) or docetaxel (700 nM) for 7 days. We further tested if 400 mg/L
of AAE (AAE active dose for hair promoting effect [20]) or the corresponding amount of vehicle
(DMSO), was able to reduce the HF dystrophy induced by the two taxanes. After 7 days of incubation,
skin biopsies were processed for histology and classified following morphological criteria [12,40,46].
In the absence of any treatment, ex-vivo cultures of HFs were mostly in Anagen (Figure 2a).
This was expected, since the hair cycle of C57BL/6 mice is fully synchronized and at week 12, all the
dorsal skins of mice belonging to this strain present HFs in anagen, a phase documented to last until
week 15 [40]. In sagittal sections, untreated HFs appear as ‘well developed’ terminal follicles, with HBs
almost totally located in the middle of subcutis, close to the panniculus carnosus (the subcutaneous
muscle layer) (Figure 2a). Moreover, transversal section clearly show fully developed ORS and IRS,
with no signs of apoptosis or fibrous tracts (Figure 2b).
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Figure 2. AAE protects murine HFs from taxanes induced dystrophy. 12 week old C57BL/6 mice
were sacrificed and their skin biopsies incubated in vitro in the absence or in the presence of Docetaxel
(700 nM), AAE (400 mg/L) or vehicle. Upon 7 days of ex-vivo culturing, biopsies were fixed and
processed for histology. Nuclei were stained with DAPI and HFs classified following morphological
criteria. (a,b) Untreated HFs in late Anagen phase; (c,d) HFs treated with Docetaxel showing severe
signs of follicular dystrophy (e,f) HFs of mice treated with docetaxel in the presence of AAE appearing
less damaged by the treatment with the taxane. Scale bars correspond to 50 µm.
Treatment with taxanes (both Docetaxel (Figure 2c,d) and Paclitaxel (data not shown)) massively
affecte HFs, hat showed clear signs of chemotherapy induced amage. In sagitt l sk n sections,
we did not detec terminal healthy follicles but, on the contrary, mostly degener ted follicular units and
HFs remnants (Figure 2c). Transversal sections sho ed dispersed fibrous tracts and the few follicles
visible presented loss of ORS layer and severe IRS wrinkling (Figure 2d).
When HFs were treated with taxanes in the presence of AAE, HFs appeared much less damaged
by the treatment (Figure 2f). Their morphology and average length were preserved as well as their
location close to the subcutis. Moreover, in transversal sections no evident signs of ORS and IRS
damage was visible (Figure 2f).
3.3. AAE Preserves Keratin Production in Murine HFs Treated with Taxanes
To confirm the pr tective effect exerted by AAE against taxane induced ystrophy, ir shaft
microstructure an keratin content of HFs were evaluated by SEM-EDX [36]. To analyse the ir shaft
extension occurred only during the period of the in vitro incubation, we evaluated only hair shafts
section located in the HFs or closest to them. Differently from untreated HFs (Figure 3a), hair shafts
of HFs treated with Docetaxel (Figure 3b,c,e,g) or Paclitaxel (data not shown) appeared frequently
damaged and when analysed by EDX presented a drastic decrease in Sulphur content (Figure 2i).
Since Cystine, Methionine, Cysteine and Cysteic acid are abundant amino acids of hair keratins, the
percentage of Sulphur in the hair shaft can be considered a measure of keratine amount. We have
already shown [21] that AAE is able to increase Sulphur content in hair keratins. Here, when the
incubation with taxanes was performed in the presence of AAE (400 mg/L), hair shaft showed
microstructure and Sulphur content similar to that of untreated HFs (Figure 2d,f,h,i).
Our morphological data and SEM-EDX analysis thus suggest that 400 mg/L AAE were able
to protect, at least in vitro, murine HFs from taxane induced dystrophy and to preserve in vitro
keratin production.
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stress and aging [19,48–50]. 
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Figure 3. AAE preserves keratin content in murine HFs treated with taxanes. Hair shafts plucked
out from mice biopsies treated as in Figure 2 were analysed by SEM-EDX. Morphology of hair shafts
extracted from untreated skin biopsies (a) or treated with docetaxel (700 nM; b,c,e,g) and showing
signs of hair shaft damage. Morphology of hair shafts extracted from HFs treated with Docetaxel in the
presence of AAE (d,f,h) showing signs of hair shaft protection exerted by AAE (Scale bars correspond
to 10 µm). (i) SEM-EDX quantitative analysis indicates a decrease in Sulphur content in hairs shafts
extracted from HFs treated with taxanes. In the presence of AAE the Sulphur content of hair shafts is
partially preserved (mean ± s.e.m.; n = 8, *** p < 0.001).
4. Discussion
Annurca Apples have been showing their potential as nutraceuticals in many human conditions
and pathologies. The plethora of different biological contexts in which AAE is active must be attributed
to the hundreds of different metabolites it contains [47]. The resulting molecular synergis allows
AAE to act as antioxidant, as modulator of lipid and cholesterol anabolism as well as agai st stress
and aging [19,48–50].
In our recently published clinical trial [20], we have proved that the consumption of AAE is
able to p omote hair growth in healthy subjects and to increase air number, hair weight and keratin
content in umans. Using a murine model and high resolution ass spectrometry we have as
well disclosed some of the olecular tails behind AAE hair promoting eff ct [21]. AAE inhibits
glutaminolysis, PPP as well as glutathione, citrulline and nucleotide synthesis switching intracellular
HFs etabolism towards mitochondrial respi atio and β-oxidation. As result of this drastic m tabolic
re-programming, amino acids are spared from being oxi ized and are ultimately kept available for
keratin biosynthesis [21].
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Herein, our analysis is further extended to show the effect exerted by AAE on PUFAs, a class of
lipids involved in HF signalling and homeostasis [23,24]. By monitoring the change in the intracellular
levels of PUFA and of their metabolites (Figure 1, Table 1 and Table S1) we could show that AAE
hijacks most of them toward β-oxidation. AAE induces PUFA epoxides conversion into inactive
diols as well as prostanoids conversion into inactive catabolites. As result, AAE promotes their
usage as β-oxidation substrates, altering the overall balance of these biologically active lipids in HFs.
Interestingly, the prostanoid PGF2α a potent hair growth promoter is one of the PUFA metabolite
that is selectively increased by AAE in HFs and likely one of the molecule contributing to the hair
promoting effect of AAE.
The metabolic switch induced by AAE in HFs has interesting consequence in terms of
compatibility of AAE with chemotherapy regimens. By blocking glutaminolysis, AAE impairs
the synthesis of nitrogen containing bases and of deoxy-nucleotides. The absence of metabolites
necessary for DNA replication and RNA production explains why AAE does not promote cancer cell
growth and mitosis [12]. Moreover, by reducing nucleotide synthesis, AAE makes HFs resistant to
chemotherapy agents like taxanes, that selectively inhibit mitotic and highly proliferating cancer cells.
This peculiar mechanism, together with the anticancer property we have described for AAE in colon
rectal cancer cells [12], suggests that AAE could represent a safe nutraceutical option for hair growth
and an interesting alternative to synthetic drugs for treating CIA.
Indeed, by using ex-vivo cultures of HFs, we prove that 400 mg/L AAE (an amount corresponding
to the daily dosage recommended for consumption in humans) reduced hair bulb dystrophy
and efficiently preserved keratin production in murine HF treated with docetaxel and paclitaxel,
two taxanes commonly causing irreversible alopecia in breast cancer patients. Ex-vivo cultures of
human HFs as well as animal models of CIA, will help in the future to finally clarify if AAE can be
elected as candidate nutraceutical against CIA.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/11/1808/s1,
Figure S1: Partial least squares-discriminant analysis (PLS-DA) of HFs metabolites determined by FT-ICR–MS,
Table S1: Identification of metabolites in HFs determined by DI-FT-ICR-MS.
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